Published in Arthritis Rheum on April 15, 2005
Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol (2011) 1.48
Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum (2008) 1.36
Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum (2009) 1.36
A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) (2010) 1.29
Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol (2009) 1.27
Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum (2006) 1.23
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.19
MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol (2006) 1.08
Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics (2011) 1.06
Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol (2008) 1.01
Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum (2010) 1.00
Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken) (2012) 1.00
Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) (2014) 0.98
Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2010) 0.97
The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum (2008) 0.92
Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis Rheum (2009) 0.92
Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease. Clin Immunol (2007) 0.84
The heterogeneity of juvenile myositis. Autoimmun Rev (2006) 0.83
Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. Arthritis Rheumatol (2016) 0.80
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med (2016) 0.78
Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. Arthritis Rheum (2010) 0.78
Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface? Arthritis Rheum (2010) 0.77
Male gender bias in autism and pediatric autoimmunity. Autism Res (2012) 0.76
[Dermatomyositis]. Z Rheumatol (2009) 0.75
Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J (2016) 0.75
Recurrence of juvenile dermatomyositis 8 years after remission. JAAD Case Rep (2016) 0.75
Acute Presentation of Juvenile Dermatomyositis with Subclinical Cardiac Involvement: A Rare Case. J Clin Diagn Res (2016) 0.75
Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol (2014) 0.75
Anasarca as the presenting manifestation of parvovirus B19 associated juvenile dermatomyositis. Rheumatol Int (2008) 0.75
Statistical analysis of real-time PCR data. BMC Bioinformatics (2006) 7.31
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med (2004) 7.12
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
Lifetime risks of cardiovascular disease. N Engl J Med (2012) 5.95
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 4.15
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Two-year follow-up results for Hip-Hop to Health Jr.: a randomized controlled trial for overweight prevention in preschool minority children. J Pediatr (2005) 2.85
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2009) 2.31
US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum (2003) 2.21
Southern Tick-Associated Rash Illness (STARI) in the North: STARI following a tick bite in Long Island, New York. Clin Infect Dis (2011) 2.19
Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol (2013) 2.00
Cancer screening in patients with systemic lupus erythematosus. J Rheumatol (2005) 1.75
Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr (2006) 1.71
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64
Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol (2007) 1.63
Childhood sarcoidosis: A rare but fascinating disorder. Pediatr Rheumatol Online J (2008) 1.63
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
Hip-Hop to Health Jr. for Latino preschool children. Obesity (Silver Spring) (2006) 1.61
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet (2011) 1.49
Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 1.47
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.43
Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet (2010) 1.43
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum (2003) 1.42
Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol (2006) 1.42
Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J (2008) 1.41
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis (2011) 1.41
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet (2012) 1.41
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.38
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum (2009) 1.37
Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg (2008) 1.36
Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med (2006) 1.34
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
Results of a faith-based weight loss intervention for black women. J Natl Med Assoc (2005) 1.30
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol (2003) 1.28
A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum (2009) 1.23
Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum (2006) 1.23
Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol (2004) 1.21
IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol (2003) 1.20
Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation (2011) 1.20
25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum (2009) 1.20
Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum (2011) 1.19
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2006) 1.16
Genetic variation in the CRP promoter: association with systemic lupus erythematosus. Hum Mol Genet (2008) 1.16
Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet (2013) 1.14
Association of traditional risk factors with cardiovascular death across 0 to 10, 10 to 20, and >20 years follow-up in men and women. Am J Cardiol (2008) 1.13
Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.12
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2010) 1.12
Malignancy and autoimmunity. Curr Opin Rheumatol (2006) 1.11
A combined breast health/weight loss intervention for Black women. Prev Med (2005) 1.10
The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol (2002) 1.10
Obesity reduction black intervention trial (ORBIT): six-month results. Obesity (Silver Spring) (2008) 1.09
Obesity reduction black intervention trial (ORBIT): 18-month results. Obesity (Silver Spring) (2010) 1.09
Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol (2006) 1.09
ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis (2009) 1.08
The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol (2010) 1.07
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis (2012) 1.07
Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.06
Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol (2009) 1.05
Disease-associated mutations at copper ligand histidine residues of superoxide dismutase 1 diminish the binding of copper and compromise dimer stability. J Biol Chem (2006) 1.05
Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol (2011) 1.04
Combined zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition interactions that modulate melanocyte pigmentation. Dis Model Mech (2010) 1.04
Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2013) 1.03
Recruiting participants with peripheral arterial disease for clinical trials: experience from the Study to Improve Leg Circulation (SILC). J Vasc Surg (2009) 1.03
Obesity and risk factors for the metabolic syndrome among low-income, urban, African American schoolchildren: the rule rather than the exception? Am J Clin Nutr (2005) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Obesity Reduction Black Intervention Trial (ORBIT): design and baseline characteristics. J Womens Health (Larchmt) (2008) 1.01
Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum (2012) 1.01
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum (2004) 1.01
Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus. Arthritis Rheum (2011) 1.01
Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum (2012) 0.99
MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet (2013) 0.99
Premature atherosclerotic disease in systemic lupus erythematosus--role of inflammatory mechanisms. Autoimmun Rev (2005) 0.99
Reach-out: a family-based diabetes prevention program for African American youth. J Natl Med Assoc (2011) 0.98
Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum (2012) 0.98
Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21. Arthritis Rheum (2011) 0.98
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum (2012) 0.98
Hip-Hop to Health Jr., an obesity prevention program for minority preschool children: baseline characteristics of participants. Prev Med (2003) 0.97
Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum (2007) 0.97
The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. Am J Nephrol (2010) 0.97
Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. Ann Rheum Dis (2012) 0.96
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum (2012) 0.96
Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics (2010) 0.96